We use cookies for a better user experience. Read our Privacy Policy

I Agree

Fibrinogen Concentrates Market Analysis, 2021 - 2031

Fibrinogen Concentrates Market (Application: General Coagulation Management, Surgery, and Others; and End User: Hospitals, ASCs, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Challenges in Managing Thromboembolic Events Linked with COVID-19 Fuel Demand for Treatment

The coronavirus disease (COVID-19) is linked with extreme inflammatory response, disordered hemostasis, and high thrombotic risk. Such findings are creating business opportunities for manufacturers in the fibrinogen concentrates market. A high incidence of thromboembolic events has been reported despite thromboprophylaxis, which is raising the question of more effective anticoagulation strategies. Thus, stakeholders in the fibrinogen concentrates market are capitalizing on this opportunity to increase the availability of treatment and products.

First-line hemostasis tests such as activated partial thromboplastin time and prothrombin time, among others, are vulnerable to many drawbacks, thus affecting their reliability and clinical relevance. This is triggering the demand for specialized hemostasis-related tests that may help to assess the thrombotic risk associated with COVID-19. Moreover, hemostasis laboratories are facing challenges in the monitoring of heparin treatment. Thus, to overcome this vulnerability of laboratories, companies are ensuring robust supply of treatment and products.

To know the scope of our report Get a Sample on Fibrinogen Concentrates Market

Rarity of Patient Population Creates Hurdles in Conducting Research Studies

The fibrinogen concentrates market is projected to expand at a favorable CAGR of ~6% during the forecast period. However, it is challenging to evaluate the efficacy of human fibrinogen concentrate (FCH) in patients with congenital fibrinogen deficiency (CFD) due to the rarity of patient population. Hence, stakeholders are expected to collaborate with researchers to conduct observational retrospective study with an additional prospective component to assess the efficacy of human fibrinogen concentrate for the treatment of acute bleeding events.

It has been found that FCH is well tolerated in patients with CFD and is effective in treating bleeding events. FCH is found to be effective and has a favorable safety profile when used as treatment for both on-demand bleeding and surgical prophylaxis in patients with afibrinogenemia.

Get a glimpse of the in-depth analysis through our Report Brochure

General Coagulation Management Applications Generate Stable Revenue Streams for Stakeholders

The fibrinogen concentrates market is expected to reach a valuation of US$ 700 Mn by 2031. The concept of targeted point-of-care bleeding management is becoming a fast growing phenomenon in the market landscape. Emerging studies are making use of fibrinogen, also known as factor I, in lieu of whole blood to facilitate clotting. Fibrinogen concentrates are being highly publicized for the management of bleeding events, since it allows the administration of a precise dose to reach a desired target level.

Manufacturers in the fibrinogen concentrates market are making products and treatments easily available for hospitals, ambulatory surgical centers, and other healthcare systems. General coagulation management applications are expected to register the highest revenue share among all application types.

Early Coagulation Therapy Holds Promising Potentials to Improve Survival Rate of Patients

The early fibrinogen concentrate administration is being preferred in complex and time-sensitive environment of pre-hospital trauma care. This helps to protect against early fibrinogen depletion, promotes rapid blood clot initiation, and clot stability. Such trends are translating into value-grab opportunities for stakeholders in the fibrinogen concentrates market.

The presence of trauma-induced coagulopathy (TIC) in severely injured and bleeding patients on admission to the emergency department (ED) is leading to increased mortality rates. In order to lower mortality rates, companies are bolstering their production capabilities to ensure the readily available treatments and products. Early and effective coagulation therapy holds promising potentials to improve survival in patients. As such, manufacturers in the fibrinogen concentrates market are gaining evidence that supports early fibrinogen supplementation in trauma patients. There is a growing demand for fibrinogen concentrate products in highly dynamic and complex environment of acute pre-hospital trauma care.

Fibrinogen Concentrate Help Decrease Bleeding Tendency, Reduce Transfusion Requirements

A significant number of deaths attributable to hemorrhage occur within the first hour of hospital arrival. This is emerging as a key driver of growth in the fibrinogen concentrates market. There is an increased emphasis on hemostatic resuscitation in pre-hospital settings and battlefield. The concept of remote damage control resuscitation (RDCR) is growing popular in the fibrinogen concentrates market, which imposes logistic challenges and requirement for hemostatic products that can be easily stored, transported, and used in the field austere environment. Thus, manufacturers are tapping into revenue opportunities in such innovative and lesser-known applications.

There is evidence that shows fibrinogen concentrate has the capability to reduce transfusions of blood products and increase survival rates of patients after severe trauma. Stakeholders are anticipated to collaborate with researchers to gain evidence via randomized controlled trials to assess how fibrinogen concentrate help to decrease bleeding tendency and reduce transfusion requirements.

Generation of Strong Data Boosts Application of Fibrinogen Concentrates for TIC

Since trauma is the leading cause of mortality with major bleeding and trauma-induced coagulopathy (TIC), fibrinogen concentrate is being publicized as the first line of treatment for TIC. Contributing factors such as initiatives to improve TIC management, generation of stronger data, and improved medical education are of paramount importance to increase better patient outcomes. Simplified practice guidance and improved access to viscoelectic testing are forming critical factors for growth of the fibrinogen concentrates market.

TIC requires different treatment strategies, which include tranexamic acid (TXA), human fibrinogen concentrate, and prothrombin complex concentrates (PCCs), among others. Manufacturers in the fibrinogen concentrates market are gaining awareness about such patient demands and requirements from healthcare systems.

Education, Network Building Significant for Improvement in Blood Products

Canadian Blood Services - a provider of lifesaving products and services in transfusion and transplantation for patients is gaining recognition for continuously improving blood products and their utilization, which results in improvement of patient quality of life. Stakeholders in the fibrinogen concentrates market are taking cues from such developments to build their network of scientists, medical experts, collaborators, and research partners to improve blood products.

Guided clinical practices are supporting national studies, which suggest that fibrinogen concentrate is equivalent to cryoprecipitate in controlled post-operative bleeding. Such insights are impacting the way cardiac patients can be treated in various healthcare facilities. Stakeholders are realizing the importance of R&D, training, education, and engagement activities that play a key role in improving blood products. On the other hand, fibrinogen concentrate is being preferred over fresh frozen plasma (FFP), since the former delivers a standardized and higher concentration of coagulation proteins.

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

Stakeholders are paying attention to the activities of the Canadian Blood Services during the ongoing COVID-19 outbreak to prioritize and effectively deploy blood products in healthcare facilities. Fibrinogen concentrates are witnessing high demand than fresh frozen plasma, owing to the benefit of low risk of virus transmission.

Though there is evidence to support early fibrinogen supplementation in trauma patients, there is a need for robust data regarding clinical benefits in patients. Hence, companies in the fibrinogen concentrates market should increase their proficiency in randomized controlled trials to assess early administration of fibrinogen concentrate as part of a coagulation factor concentrate-based treatment strategy.

Fibrinogen Concentrates Market: Overview

  • Fibrinogen is a soluble protein, also known as coagulation factor I in the plasma that is broken down to fibrin by the enzyme thrombin to form clots
  • Human fibrinogen concentrates have been used for substitution therapy in cases of hypofibrinogenemia, dysfibrinogenemia, and afibrinogenemia. Commercially available human fibrinogen concentrate is virus-inactivated. Hence, it plays a critical role in hemostasis, especially in bleeding patients with an acquired fibrinogen deficiency.
  • Rise in demand for fibrinogen among physicians as blood clot formation agents, increase in the number of cases of bleeding disorders, and surge in the availability of fibrinogen products are key factors projected to drive the global fibrinogen concentrates market during the forecast period. Furthermore, increase in investment in research & development (R&D) and large number of products under pipeline offer significant opportunities in the market.
  • In November 2018, Octapharma received marketing authorization from the Swiss Agency for therapeutic products for fibryga, a lyophilized fibrinogen concentrate for intravenous infusion indicated for the treatment of congenital and acquired fibrinogen deficiencies

Market Segmentation: Fibrinogen Concentrates Market

  • In terms of application, the global fibrinogen concentrates market has been classified into general coagulation management, surgery, and others
  • Based on end user, the global fibrinogen concentrates market has been divided into hospitals, ASCs, and others
  • Each of the segments has been analyzed in detail for trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The fibrinogen concentrates market report provides current and future revenue (US$ Mn) for each of these segments for the period from 2017 to 2031, considering 2020 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2021 to 2031, along with market size estimations.

Regional Overview: Fibrinogen Concentrates Market

  • In terms of region, the global fibrinogen concentrates market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
  • Europe held a significant share of the global fibrinogen concentrates market in 2020, followed by North America. Europe is likely to retain market share during the forecast period. High awareness about the availability of different brands of fibrinogen concentrate products and early introduction of fibrinogen concentrates drive the market in the region.
  • Asia Pacific is likely to gain market share during the forecast period. Product launches, acquisitions, distribution agreements, alliances, and geographical expansion by players, especially in China and Japan, are projected to propel the fibrinogen concentrates market in the region.
  • Current and future market sizes in terms of value (US$ Mn) of these regional markets and major countries have been provided in the fibrinogen concentrates market report for the period from 2017 to 2031, along with their CAGRs for the period from 2021 to 2031
  • The study also offers a list of recommendations, highlights, and useful insights of the market, which are likely to help new companies willing to enter the fibrinogen concentrates market and existing companies to increase market share and in the decision-making process

Major Players: Fibrinogen Concentrates Market

  • The report concludes with the company profiles section that includes key information about the major players in the global fibrinogen concentrates market
  • Leading players analyzed in the fibrinogen concentrates market report are
    • LFB GROUP
    • Green Cross Corp.
    • Octapharma AG
    • CSL Behring
    • Shanghai RAAS
  • Each of these players has been profiled in the fibrinogen concentrates market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Fibrinogen Concentrates Market – Segmentation

TMR’s study on the global fibrinogen concentrates market includes information divided into three segments: application, end user, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global fibrinogen concentrates market have been discussed in detail.

Application
  • General Coagulation Management
  • Surgery
  • Others
End User
  • Hospitals
  • ASCs
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Fibrinogen Concentrates Market Analysis, 2021 - 2031

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of fibrinogen concentrates market?

The global fibrinogen concentrates market was worth US$ 350 Mn and is projected to reach a value of US$ 700 Mn by the end of 2031

What is the anticipated CAGR of the fibrinogen concentrates market in the forecast period?

Fibrinogen concentrates market is anticipated to grow at a CAGR of 6% during the forecast period

Which region is expected to project the highest share in fibrinogen concentrates market?

Europe accounted for a major share of the global fibrinogen concentrates market

What are the key driving factors for the growth of the fibrinogen concentrates market?

Fibrinogen concentrates market is driven by rise in demand for fibrinogen among physicians as blood clot formation agents, increase in the number of cases of bleeding disorders, and surge in the availability of fibrinogen products are key factors projected to drive the global market

Who are the key players in the fibrinogen concentrates market?

Key players in the global fibrinogen concentrates market include LFB GROUP, Green Cross Corp., Octapharma AG, CSL Behring, and Shanghai RAAS

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Fibrinogen Concentrates Market 

4. Market Overview

    4.1. Introduction & Overview

    4.2. Market Dynamics

        4.2.1. Drivers

        4.2.2. Restraints

        4.2.3. Opportunities 

    4.3. Global Fibrinogen Concentrates Market Analysis and Forecast, 2017–2031

5. Market Outlook 

    5.1. Disease Prevalence & Incidence Rate Globally with Key Countries

    5.2. Pipeline Analysis

    5.3. Clinical Trail Analysis

    5.4. COVID-19 Impact Analysis 

6. Global Fibrinogen Concentrates Market Analysis and Forecast, by Application 

    6.1. Introduction & Definition

    6.2. Global Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by Application, 2017–2031

        6.2.1. General Coagulation Management

        6.2.2. Surgery

        6.2.3. Others

    6.3. Global Fibrinogen Concentrates Market Attractiveness Analysis, by Application 

7. Global Fibrinogen Concentrates Market Analysis and Forecast, by End-user

    7.1. Introduction & Definition

    7.2. Global Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        7.2.1. Hospitals

        7.2.2. ASCs

        7.2.3. Others

    7.3. Global Fibrinogen Concentrates Market Attractiveness Analysis, by End-user

8. Global Fibrinogen Concentrates Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Global Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific

        8.2.4. Latin America

        8.2.5. Middle East & Africa

    8.3. Global Fibrinogen Concentrates Market Attractiveness Analysis, by Region

9. North America Fibrinogen Concentrates Market Analysis and Forecast

    9.1. Introduction 

    9.2. North America Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by Application, 2017–2031

        9.2.1.  General Coagulation Management

        9.2.2.  Surgery

        9.2.3.  Others

    9.3. North America Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        9.3.1.  Hospitals

        9.3.2.  ASCs

        9.3.3.  Others 

    9.4. North America Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by Country, 2017–2031

        9.4.1. U.S.

        9.4.2. Canada

    9.5. North America Fibrinogen Concentrates Market Attractiveness Analysis

        9.5.1.  By Application 

        9.5.2.  By End-user

        9.5.3.  By Country 

10. Europe Fibrinogen Concentrates Market Analysis and Forecast

    10.1. Introduction 

    10.2. Europe Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by Application, 2017–2031

        10.2.1. General Coagulation Management

        10.2.2. Surgery

        10.2.3. Others

    10.3. Europe Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        10.3.1. Hospitals

        10.3.2. ASCs

        10.3.3. Others

    10.4. Europe Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe

    10.5. Europe Fibrinogen Concentrates Market Attractiveness Analysis

        10.5.1. By Application 

        10.5.2. By End-user

        10.5.3. By Country/Sub-region

11. Asia Pacific Fibrinogen Concentrates Market Analysis and Forecast

    11.1. Introduction 

    11.2. Asia Pacific Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by Application, 2017–2031

        11.2.1. General Coagulation Management

        11.2.2. Surgery

        11.2.3. Others

    11.3. Asia Pacific Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        11.3.1. Hospitals

        11.3.2. ASCs

        11.3.3. Others

    11.4. Asia Pacific Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Asia Pacific Fibrinogen Concentrates Market Attractiveness Analysis

        11.5.1. By Application 

        11.5.2. By End-user

        11.5.3. By Country/Sub-region

12. Latin America Fibrinogen Concentrates Market Analysis and Forecast

    12.1. Introduction 

    12.2. Latin America Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by Application, 2017–2031

        12.2.1. General Coagulation Management

        12.2.2. Surgery

        12.2.3. Others

    12.3. Latin America Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        12.3.1. Hospitals

        12.3.2. ASCs

        12.3.3. Others

    12.4. Latin America Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Latin America Fibrinogen Concentrates Market Attractiveness Analysis

        12.5.1. By Application 

        12.5.2. By End-user

        12.5.3. By Country/Sub-region

13. Middle East & Africa Fibrinogen Concentrates Market Analysis and Forecast

    13.1. Introduction 

    13.2. Middle East & Africa Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by Application, 2017–2031

        13.2.1. General Coagulation Management

        13.2.2. Surgery

        13.2.3. Others

    13.3. Middle East & Africa Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        13.3.1. Hospitals

        13.3.2. ASCs

        13.3.3. Others

    13.4. Middle East & Africa Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Middle East & Africa Fibrinogen Concentrates Market Attractiveness Analysis

        13.5.1. By Application 

        13.5.2. By End-user

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Market Position Analysis, by Company, 2020

    14.2. Company Profiles

        14.2.1. LFB GROUP

            14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.1.2. Growth Strategies

            14.2.1.3. SWOT Analysis

        14.2.2. Green Cross Corp. 

            14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.2.2. Growth Strategies

            14.2.2.3. SWOT Analysis

        14.2.3. Octapharma AG

            14.2.3.1. Company Overview (HQ, Business Segments)

            14.2.3.2. Growth Strategies

            14.2.3.3. SWOT Analysis

        14.2.4. CSL Behring

            14.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.4.2. Growth Strategies

            14.2.4.3. SWOT Analysis

        14.2.5. Shanghai RAAS 

            14.2.5.1. Company Overview (HQ, Business Segments)

            14.2.5.2. Growth Strategies

            14.2.5.3. SWOT Analysis

List of Tables

Table 01: Clinical Trials (1/6)

Table 02: Clinical Trials (1/6)

Table 03: Clinical Trials (1/6)

Table 04: Clinical Trials (1/6)

Table 05: Clinical Trials (1/6)

Table 06: Clinical Trials (1/6)

Table 07: Global Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 08: Global Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 09: Global Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 10: North America Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 11: North America Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 12: North America Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 13: Europe Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Europe Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 15: Europe Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 16: Asia Pacific Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Asia Pacific Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 18: Asia Pacific Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 19: Latin America Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 20: Latin America Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 21: Latin America Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 22: Middle East & Africa Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 23: Middle East & Africa Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 24: Middle East & Africa Fibrinogen Concentrates Market Value (US$ Mn) Forecast, by End-user, 2017–2031

List of Figures

Figure 01: Market Share, by Application

Figure 02: Market Share, by End-user

Figure 03: Regional Share Snapshot

Figure 04: Global Fibrinogen Concentrates Market Value (US$ Mn) Forecast, 2017–2031

Figure 05: Global Fibrinogen Concentrates Market Value Share, by End-user, 2020

Figure 06: Global Fibrinogen Concentrates Market Value Share, by Region, 2020

Figure 07: Global Fibrinogen Concentrates Market Value Share, by Application, 2020

Figure 08 : Disease Prevalence & Incidence Rate Globally and Key Countries

Figure 09: Pipeline Analysis

Figure 10: Confirmed Cases in Different Regions

Figure 11: Cumulative Total Confirmed & Death Cases in Top Countries 

Figure 12: Global Fibrinogen Concentrates Market Value Share Analysis, by Application, 2020 and 2031

Figure 13: Global Fibrinogen Concentrates Market Attractiveness Analysis, by Application, 2021–2031

Figure 14: Global Fibrinogen Concentrates Market Value (US$ Mn), by General Coagulation Management, 2017–2031

Figure 15: Global Fibrinogen Concentrates Market Value (US$ Mn), by Surgery, 2017–2031

Figure 16: Global Fibrinogen Concentrates Market Value (US$ Mn), by Others (obstetric bleeding, etc.), 2017–2031

Figure 17: Global Fibrinogen Concentrates Market Value Share Analysis, by End-user, 2020 and 2031

Figure 18: Global Fibrinogen Concentrates Market Attractiveness Analysis, by End-user, 2021–2031

Figure 19: Global Fibrinogen Concentrates Market Value (US$ Mn), by Hospitals, 2017–2031

Figure 20: Global Fibrinogen Concentrates Market Value (US$ Mn), by ASCs, 2017–2031

Figure 21: Global Fibrinogen Concentrates Market Value (US$ Mn), by Others, 2017–2031

Figure 22: Global Fibrinogen Concentrates Market Analysis, by Region, 2020

Figure 23: Global Fibrinogen Concentrates Market Value Share Analysis, by Region, 2020 and 2031

Figure 24: Global Fibrinogen Concentrates Market Attractiveness Analysis, by Region, 2021–2031

Figure 25: North America Fibrinogen Concentrates Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 26: North America Fibrinogen Concentrates Market Value Share, by Country, 2020–2031

Figure 27: North America Fibrinogen Concentrates Market Attractiveness, by Country, 2021–2031

Figure 28: North America Fibrinogen Concentrates Market Value Share Analysis, by Application, 2020 and 2031

Figure 29: North America Fibrinogen Concentrates Market Attractiveness Analysis, by Application, 2021–2031

Figure 30: North America Fibrinogen Concentrates Market Value Share Analysis, by End-user, 2020 and 2031

Figure 31: North America Fibrinogen Concentrates Market Attractiveness Analysis, by End-user, 2021–2031

Figure 32: Europe Fibrinogen Concentrates Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 33: Europe Fibrinogen Concentrates Market Value Share, by Country/Sub-region, 2020–2031

Figure 34: Europe Fibrinogen Concentrates Market Attractiveness, by Country/Sub-region, 2021–2031

Figure 35: Europe Fibrinogen Concentrates Market Value Share Analysis, by Application, 2020 and 2031

Figure 36: Europe Fibrinogen Concentrates Market Attractiveness Analysis, by Application, 2021–2031

Figure 37: Europe Fibrinogen Concentrates Market Value Share Analysis, by End-user, 2020 and 2031

Figure 38: Europe Fibrinogen Concentrates Market Attractiveness Analysis, by End-user, 2021–2031

Figure 39: Asia Pacific Fibrinogen Concentrates Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 40: Asia Pacific Fibrinogen Concentrates Market Value Share, by Country/Sub-region, 2020–2031

Figure 41: Asia Pacific Fibrinogen Concentrates Market Attractiveness, by Country/Sub-region, 2021–2031

Figure 42: Asia Pacific Fibrinogen Concentrates Market Value Share Analysis, by Application, 2020 and 2031

Figure 43: Asia Pacific Fibrinogen Concentrates Market Attractiveness Analysis, by Application, 2021–2031

Figure 44: Asia Pacific Fibrinogen Concentrates Market Value Share Analysis, by End-user, 2020 and 2031

Figure 45: Asia Pacific Fibrinogen Concentrates Market Attractiveness Analysis, by End-user, 2021–2031

Figure 46: Latin America Fibrinogen Concentrates Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 47: Latin America Fibrinogen Concentrates Market Value Share, by Country/Sub-region, 2020–2031

Figure 48: Latin America Fibrinogen Concentrates Market Attractiveness, by Country/Sub-region, 2021–2031

Figure 49: Latin America Fibrinogen Concentrates Market Value Share Analysis, by Application, 2020 and 2031

Figure 50: Latin America Fibrinogen Concentrates Market Attractiveness Analysis, by Application, 2021–2031

Figure 51: Latin America Fibrinogen Concentrates Market Value Share Analysis, by End-user, 2020 and 2031

Figure 52: Latin America Fibrinogen Concentrates Market Attractiveness Analysis, by End-user, 2021–2031

Figure 53: Middle East & Africa Fibrinogen Concentrates Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 54: Middle East & Africa Fibrinogen Concentrates Market Value Share, by Country/Sub-region, 2020–2031

Figure 55: Middle East & Africa Fibrinogen Concentrates Market Attractiveness, by Country/Sub-region, 2021–2031

Figure 56: Middle East & Africa Fibrinogen Concentrates Market Value Share Analysis, by Application, 2020 and 2031

Figure 57: Middle East & Africa Fibrinogen Concentrates Market Attractiveness Analysis, by Application, 2021–2031

Figure 58: Middle East & Africa Fibrinogen Concentrates Market Value Share Analysis, by End-user, 2020 and 2031

Figure 59: Middle East & Africa Fibrinogen Concentrates Market Attractiveness Analysis, by End-user, 2021–2031

Figure 60: Global Fibrinogen Concentrates Market Share, by Company, 2020

Figure 61: Green Cross Corp. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2020

Figure 62: Green Cross Corp. Operating Income (US$ Mn) and Y-o-Y Growth (%), 2018–2020

Figure 63: Green Cross Corp. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2020

Figure 64: Green Cross Corp. Net Income (US$ Mn) and Y-o-Y Growth (%), 2018–2020

Figure 65: Octapharma AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2020

Figure 66: Octapharma AG Operating Income 

Figure 67: Octapharma AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2020

Figure 68: Octapharma AG Net Income (US$ Mn) and Y-o-Y Growth (%), 2018–2020

Figure 69: CSL Behring Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2020

Figure 70: CSL Behring Operating Income (US$ Mn) and Y-o-Y Growth (%), 2018–2020

Figure 71: CSL Behring R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2020

Figure 72: CSL Behring Net Income (US$ Mn) and Y-o-Y Growth (%), 2018–2020

Figure 73: CSL Behring Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2020

Figure 74: CSL Behring Operating Income (US$ Mn) and Y-o-Y Growth (%), 2018–2020

Figure 75: CSL Behring R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2020

Figure 76: CSL Behring Net Income (US$ Mn) and Y-o-Y Growth (%), 2018–2020

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

143

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved